Table of Content - Achondroplasia Treatment Market

Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.

Market Dynamics

Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.

Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.

Key features of the study:

This report provides an in-depth analysis of the global achondroplasia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Achondroplasia Treatment market based on the following parameters– Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.

Detailed Segmentation:

Global Achondroplasia Treatment Market, By Treatment Type:
- Vosoritide
- Human Growth Hormone
- Others
Global Achondroplasia Treatment Market, By Route of Administration:
- Oral
- Parenteral
Global Achondroplasia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Achondroplasia Treatment, By Region:
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- BioMarin
- RIBOMIC
- Ascendis Pharma A/S
- BridgeBio Pharma, Inc.
- Pfizer Inc.
- PhaseBio Pharmaceuticals, Inc.
- SiSaf
- Novo Nordisk A/S
- Hoffmann-La Roche Ltd
- LG Chem
- Ferring B.V.
- JCR Pharmaceuticals Co., Ltd
- KVK TECH, INC.
- VIVUS LLC.
- ProLynx Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Ipsen Pharma
- Novartis AG
- Xiamen Amoytop Biotech Co., Ltd.

Table of Contents

Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Treatment Type
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Distribution Channel
  - Market Snippet, By Region
  - Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
Global Achondroplasia Treatment Market, COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
Global Achondroplasia Treatment Market, By Treatment Type, 2020 – 2032 (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021–2032
  - Segment Trends
- Vosoritide
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
- Human Growth Hormone
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Global Achondroplasia Treatment Market, By Route of Administration, 2020 – 2032 (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021–2032
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
- Parenteral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Global Achondroplasia Treatment Market, By Distribution Channel, 2020 – 2032 (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021–2032
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Mn)
Global Achondroplasia Treatment Market, By Regions, 2020 – 2032 (US$ Mn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021–2032
  - Segment Trends
- North America
  - Introduction
  - Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Country, 2020 – 2032, (US$ Mn)
    - U.S.
    - Canada
- Europe
  - Introduction
  - Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Country, 2020 – 2032, (US$ Mn)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Country, 2020 – 2032, (US$ Mn)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Introduction
  - Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Country, 2020 – 2032, (US$ Mn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Middle East
  - Introduction
  - Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Country, 2020 – 2032, (US$ Mn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020 – 2032, (US$ Mn)
  - Market Size and Forecast, Y-o-Y Growth and By Country, 2020 – 2032, (US$ Mn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Company Profiles
  - BioMarin
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - RIBOMIC
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Ascendis Pharma A/S
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - BridgeBio Pharma, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Pfizer Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - PhaseBio Pharmaceuticals, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - SiSaf
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Novo Nordisk A/S
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - F.Hoffmann-La Roche Ltd
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - LG Chem
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Ferring B.V.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - JCR Pharmaceuticals Co., Ltd
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - KVK TECH, INC.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - VIVUS LLC.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - ProLynx Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Teva Pharmaceutical Industries Ltd.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Eli Lilly and Company
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Ipsen Pharma
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Novartis AG
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Xiamen Amoytop Biotech Co., Ltd.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
Section
- References
- Research Methodology
- About us and Sales Contact

*Browse 30 market data tables and 24 figures on “Achondroplasia Treatment Market – Global forecast to 2032

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE